R&D Systems Inc. Tocris Bioscience Boston Biochem

Crizotinib

Cat. No. 4368

Crizotinib C21H22Cl2FN5O [877399-52-5]

Price and Availability

For Crizotinib pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Names: PF 02341066, PF 2341066

Chemical Name: 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

Biological Activity

Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

M.Wt:
450.34
Formula:
C21H22Cl2FN5O
Solubility:
Soluble to 10 mM in DMSO and to 100 mM in 2eq.HCl
Purity:
>99 %
Storage:
Store at +4°C
CAS No:
877399-52-5

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Christensen et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol.Cancer Ther. 6 3314. PMID: 18089725.

Zou et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 4408. PMID: 17483355.

Cui et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J.Med.Chem. 54 6342. PMID: 21812414.

If you know of a relevant citation for this product please let us know.

Keywords: Crizotinib, supplier, c-MET, alk, anaplastic, lymphoma, kinases, antitumor, selective, potent, PF2341066, PF02341066

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Guide

Highlights over 350 products for cancer research. Request a copy or view PDF today.

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 350 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

New Product Guide

NPG

Highlights 150 new products added in the second half of 2014. View PDF today.

divider line

New Products in this Area

PKI 166 hydrochloride

Potent EGFR-kinase inhibitor

ASP 3026

Potent anaplastic lymphoma kinase (ALK) inhibitor

KYL

EphA4 receptor tyrosine kinase antagonist; neuroprotective

PD 90780

Inhibits NGF binding to p75NTR

LM11A 31 dihydrochloride

Nonpeptide p75NTR ligand; neuroprotective

EG 00229

Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to NRP1

Toceranib

Potent PDGFR and VEGFR inhibitor

NVP ADW 742

ATP-competitive inhibitor of IGF1R

Sign-up for new product e-alerts
divider line

Bio-Techne Events

DPG 2015

11th Göttingen Meeting of the German Neuroscience Society

March 18 - 21, 2015

Göttingen University, Germany

Booth: 39